US FDA Sentinel network planning should focus on privacy concerns, GAO says
This article was originally published in Scrip
Executive Summary
The US FDA should create a milestones plan for developing the Sentinel active postmarketing safety surveillance system and addressing related privacy and security concerns, the Government Accountability Office (GAO) said.